Form 4: Organon CHRO Falcione Reports Planned Equity Transactions

Organon & Co.'s Chief Human Resources Officer, Aaron Falcione, reported planned future acquisitions and dispositions of common stock related to performance share units and dividend equivalents under a Rule 10b5-1 plan.

Summary

• Aaron Falcione, Chief Human Resources Officer of Organon & Co., reported planned future transactions under a Rule 10b5-1 plan.
• On February 27, 2026, Falcione is set to acquire 23,805 shares of common stock from the release of performance share units (PSUs) at a price of $0.
• An additional 6,717 shares are planned for acquisition from dividend equivalents on these PSUs, also at a price of $0.
• Concurrently, 8,705 shares are planned for disposition at $7.17 and 2,301 shares at $7.23 to cover tax withholding obligations related to these equity awards.
• The filing also includes the addition of 1,619.41 shares of common stock acquired from dividend equivalents net of withholding tax not previously required to be reported.
• Following these planned transactions, Falcione's beneficial ownership will be 84,109.071 shares of Organon & Co. common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive event, reflecting the routine vesting of executive equity compensation due to performance goal attainment, which aligns executive interests with shareholders, despite the necessary tax-related dispositions.

Positives

• The planned acquisition of 23,805 shares from performance share units indicates that performance goals were met, leading to the vesting of these awards.
• The planned acquisition of 6,717 shares from dividend equivalents reflects additional value accrued on the vested PSUs.
• The inclusion of 1,619.41 shares from dividend equivalents net of withholding tax further increases beneficial ownership.

Negatives

• The planned disposition of 8,705 shares and 2,301 shares is solely for covering tax withholding obligations, which reduces the net shares retained by the executive.

Risks

• This Form 4 filing primarily details individual insider transactions and does not contain company-specific risk factors or disclosures.

Future Outlook

The filing details pre-planned future transactions scheduled for February 27, 2026, under a Rule 10b5-1 plan, indicating the anticipated vesting of equity awards and associated tax dispositions. It does not provide broader company-specific forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that these are routine insider transactions related to executive equity compensation, specifically the vesting of performance share units and dividend equivalents, along with tax-related sales. Such pre-planned transactions under Rule 10b5-1 plans are common across industries for executive retention and motivation, providing transparency into future insider stock movements.

Comparison to Industry Standards

• Not applicable for an individual insider transaction report, as this filing does not contain company performance metrics or strategic updates that can be benchmarked against industry standards or competitors.

Corporate Governance

Related Party Transactions

• The reported transactions involve the acquisition and disposition of Organon & Co. common stock by Aaron Falcione, an officer of the company, which are considered related party transactions as they pertain to executive compensation.

Stakeholder Impact

• Shareholders: The vesting of performance share units indicates that company performance goals were met, which can be viewed positively as it aligns executive incentives with shareholder value creation.
• Aaron Falcione (Reporting Person): These transactions directly impact his personal equity holdings in Organon & Co., increasing his beneficial ownership after accounting for tax withholdings.

Key Dates

Recommendation

This Form 4 details routine equity compensation vesting and tax-related dispositions for an executive, pre-planned under a Rule 10b5-1 plan. It does not provide new information about the company's operational or financial performance that would alter an investment thesis, thus a 'hold' recommendation is appropriate as it's a neutral event for the stock's fundamental outlook.

Keywords

Organon, OGN, Aaron Falcione, Form 4, insider transaction, equity compensation, performance share units, dividend equivalents, Rule 10b5-1 plan, CHRO, beneficial ownership